Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023

NEW YORK, May 17, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data... | May 17, 2023

Related Keywords

North Carolina ,United States ,Raleigh ,France ,Paris ,France General ,New York ,American ,Beatriz Aranda Orgilles ,Mark Frattini ,Daniel Lee ,Arthur Stril ,Pascalyne Wilson ,Ashleyr Robinson ,American Society Of Hematology ,Cellectis The Company Euronext Growth ,Nasdaq ,Securities Exchange Commission ,Clinical Sciences At Cellectis ,Team Leader At Cellectis ,American Society Of Gene ,Euronext Growth ,American Society ,Cell Therapy ,Clinical Data ,Dose Regimen ,Chief Medical Officer ,Phasei Trial ,Adult Patients ,Acute Myeloid Leukemia ,Clinical Sciences ,Production Advances ,Targeting Hematologic ,Solid Tumor ,Abstract Number ,Team Leader ,Multiplex Engineering ,Superior Generation ,Wednesday Poster ,Board Number ,Nasdaq Global Market ,Private Securities Litigation Reform Act ,Annual Report ,Chief Business Officer ,Lifesci Advisors ,Cellectis Sa Stock Exchange ,News ,Information ,Press Release ,Few ,Bay ,023 ,Cellectis ,Biotechnology ,Company ,Sing ,Its ,Ioneering ,Platform ,O ,Evelop ,Fell ,End ,Gene ,Oday ,Presents ,Linical Alcls Fr0010425595 ,